Dr. Xue Hou 侯雪
Chief Physician
Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Chemotherapy, targeted therapy, immunotherapy, and multidisciplinary care for lung cancer, pleural mesothelioma, and thymic tumors. Specializes in perioperative lung cancer treatment and management of brain metastases.
Dr. Hou holds a PhD in Oncology from Sun Yat-sen University Cancer Center (SYSUCC) and completed undergraduate studies at SYSU School of Medicine. Training includes residency at Shanghai Chest Hospital and roles at SYSUCC since 2011. Dr. Hou was a visiting scholar at Memorial Sloan Kettering Cancer Center (2014–2015) and was named to the SYSUCC Excellent Young Talent Program.
Professional roles
- Vice Chair, Brain Metastasis Professional Committee, Guangdong Chest Tumor Prevention and Treatment Research Association
- Standing Committee Member, Youth Committee of Chemotherapy Professional Committee, Guangdong Anti-Cancer Association
- Standing Committee Member, Lung Cancer Professional Committee, Guangdong Female Physicians Association
- Member, Precision Medicine Professional Committee, Guangdong Clinical Medical Society
Name order: in Chinese the family name comes first (Hou Xue). Papers usually list the name as Xue Hou or Hou X.
Selected publications
93 papers on PubMed matched by name and affiliation; 16 as first or senior author since 2016. Most recent first- or senior-author papers:
- Lung Cancer, 2026 (senior author): Dietary inflammatory index and lung cancer risk: multi-cohort evidence and plasma proteomic profiles. PubMed 42349085
- Transl Lung Cancer Res, 2026 (senior author): Real-world insights into multidisciplinary management and outcomes of stage III (N2-3) non-small cell lung cancer. PubMed 41808719
- EClinicalMedicine, 2025 (first author): First-line camrelizumab plus pemetrexed and carboplatin for advanced non-squamous non-small-cell lung cancer with brain metastases (CAP-BRAIN): final results of a multicentre, open-label, single-arm, phase 2 trial in China. PubMed 41324015
- Clin Lung Cancer, 2025 (senior author): Efficacy and Safety of First-Line Anti-PD-1 Antibody Combined With Taxane-Platinum Versus Taxane-Platinum Alone in Metastatic Thymic Carcinoma: A Real-World Retrospective Study. PubMed 40713214
- Cell Oncol (Dordr), 2025 (senior author): Correction to: Cancer-associated fibroblasts and metabolic reprogramming predict pathologic response to neoadjuvant PD-1 blockade in resected non-small cell lung cancer. PubMed 40408018
- Cell Oncol (Dordr), 2025 (senior author): Cancer-associated fibroblasts and metabolic reprogramming predict pathologic response to neoadjuvant PD-1 blockade in resected non-small cell lung cancer. PubMed 40358847
- Cancer Treat Res Commun, 2025 (senior author): Furmonertinib rechallenge for first-line third-generation EGFR TKI-resistant EGFR-mutant NSCLC: A retrospective propensity score-matched cohort study. PubMed 40967060
- J Thorac Oncol, 2023 (first author): Efficacy, Safety, and Health-Related Quality of Life With Camrelizumab Plus Pemetrexed and Carboplatin as First-Line Treatment for Advanced Nonsquamous NSCLC With Brain Metastases (CAP-BRAIN): A Multicenter, Open-Label, Single-Arm, Phase 2 Study. PubMed 36738928
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that the papers match this doctor's specialty; this check is automatic.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion